Published in Medical Letter on the CDC and FDA, September 28th, 2003
The net loss for the year was $3,327,000, or $0.22 per share, compared to a net loss of $9,478,000, or $0.63 per share, for the year ended July 31, 2002, a decrease of 65%.
Total operating expenses for the year were $4,465,000 compared to $13,886,000 in the prior year, a decline of over 67%. A substantial portion of the losses in both the current fiscal year and prior fiscal year was due to write-downs of assets in the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.